Results · Apr-Jun 2026 · filed 5 Aug 2026
Neuland Laboratories Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 119% to ₹642 crore from ₹293 crore in Apr-Jun 2025.
Operating profit grew 546% to ₹223 crore, an operating margin of 34.7% (up 23.0 points from a year ago).
Net profit grew 962% to ₹148 crore from ₹13.9 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −17%, net profit −31%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 641.6 | 292.8 | +119% |
| Operating profit (EBITDA) | 222.9 | 34.5 | +546% |
| Operating margin | 34.7% | 11.8% | +23.0 pts |
| Net profit | 147.7 | 13.9 | +962% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 6 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 5 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 5 Aug 2026Disclosure Under Regulation 30 Of SEBI Listing Regulations
- 5 Aug 2026Disclosure Under Regulation 30 Of SEBI Listing Regulations
- 5 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 5 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.